Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ZN-c3 |
Trade Name | |
Synonyms | ZNc3|ZN c3|azenosertib |
Drug Descriptions |
ZN-c3 is a small molecular inhibitor of WEE1 and inhibition of WEE1 increases DNA damage in cancer cells to induce programmed cell death (J Clin Oncol 41, 2023 (suppl 16; abstr 5513)). |
DrugClasses | WEE1 Inhibitor 8 |
CAS Registry Number | NA |
NCIT ID | C167064 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Pembrolizumab + ZN-c3 | Bevacizumab Pembrolizumab ZN-c3 | 0 | 1 |
Bevacizumab + ZN-c3 | Bevacizumab ZN-c3 | 0 | 1 |
Carboplatin + Pembrolizumab + ZN-c3 | Carboplatin Pembrolizumab ZN-c3 | 0 | 1 |
Carboplatin + ZN-c3 | Carboplatin ZN-c3 | 0 | 1 |
Cetuximab + Encorafenib + ZN-c3 | Cetuximab Encorafenib ZN-c3 | 0 | 1 |
Gemcitabine + ZN-c3 | Gemcitabine ZN-c3 | 0 | 1 |
Niraparib + ZN-c3 | Niraparib ZN-c3 | 0 | 1 |
Paclitaxel + ZN-c3 | Paclitaxel ZN-c3 | 0 | 0 |
Pegylated liposomal doxorubicin + ZN-c3 | Pegylated liposomal doxorubicin ZN-c3 | 0 | 1 |
Pembrolizumab + ZN-c3 | Pembrolizumab ZN-c3 | 0 | 1 |
Talazoparib + ZN-c3 | Talazoparib ZN-c3 | 0 | 1 |
Trastuzumab deruxtecan + ZN-c3 | Trastuzumab deruxtecan ZN-c3 | 0 | 1 |
ZN-c3 | ZN-c3 | 0 | 6 |
ZN-c3 + ZN-d5 | ZN-c3 ZN-d5 | 0 | 1 |